COMPOSITIONS AND METHODS FOR INHIBITING MELANOCORTIN 2 RECEPTOR AND CYTOCHROME P450 11B1 EXPRESSION

Disclosed are oligonucleotides for inhibiting or reducing expression of MC2R or CYP11B1, and lipid conjugated oligonucleotides for targeting MC2R or CYP11B1 in the adrenal gland. Also disclosed are methods for treating, preventing, and alleviating diseases associated with MC2R and/or CYP11B1 express...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JOSHI, Sanjana, DUDEK, Henrik, DISTEFANO, Peter Victor, ABRAMS, Marc, WONDIMU, Elisabeth
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator JOSHI, Sanjana
DUDEK, Henrik
DISTEFANO, Peter Victor
ABRAMS, Marc
WONDIMU, Elisabeth
description Disclosed are oligonucleotides for inhibiting or reducing expression of MC2R or CYP11B1, and lipid conjugated oligonucleotides for targeting MC2R or CYP11B1 in the adrenal gland. Also disclosed are methods for treating, preventing, and alleviating diseases associated with MC2R and/or CYP11B1 expression, such as Cushing's Disease, Cushing's Syndrome, Familial Glucocorticoid Deficiency, hereditary adrenocortical unresponsiveness to ACTH, Congenital Adrenal Hypoplasia, familial Addison's Disease, or other cortisol synthesis or signaling pathway associated conditions or complications, comprising administering an effective amount of the oligonucleotides, alone or in combination to a patient. L'invention divulgue des oligonucléotides pour inhiber ou réduire l'expression de MC2R ou CYP11B1, et des oligonucléotides conjugués à des lipides pour cibler MC2R ou CYP11B1 dans la glande surrénale. L'invention divulgue également des méthodes de traitement, de prévention et d'atténuation de maladies associées à l'expression de MC2R et/ou CYP11B1, telles que la maladie de Cushing, le syndrome de Cushing, le déficit familial isolé en glucocorticoïdes, la résistance à l'Adrénocorticotrophine Hormone (ACTH) héréditaire, l'hyperplasie congénitale des surrénales, la maladie d'Addison familiale, ou d'autres affections ou complications associées à la synthèse de cortisol ou à la voie de signalisation, comprenant l'administration d'une quantité efficace des oligonucléotides, seuls ou en combinaison à un patient.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023060141A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023060141A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023060141A23</originalsourceid><addsrcrecordid>eNqNjEEKwjAURLtxIeodPrgWkrR236a_JmDyQxJQV6WUuBIt1PtjBA_gapiZN7MuJknGUdBRkw3Q2A4MRkVdgJ48aKt0mzt7yvG5sSTJZwcCPEp0MSPfibxFksqTQXDVkQHnLQe8Oo8h5N9tsbqPjyXtfrop9j1GqQ5pfg1pmccpPdN7uJBgomQ14xVvRPkf9QHNojS7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPOSITIONS AND METHODS FOR INHIBITING MELANOCORTIN 2 RECEPTOR AND CYTOCHROME P450 11B1 EXPRESSION</title><source>esp@cenet</source><creator>JOSHI, Sanjana ; DUDEK, Henrik ; DISTEFANO, Peter Victor ; ABRAMS, Marc ; WONDIMU, Elisabeth</creator><creatorcontrib>JOSHI, Sanjana ; DUDEK, Henrik ; DISTEFANO, Peter Victor ; ABRAMS, Marc ; WONDIMU, Elisabeth</creatorcontrib><description>Disclosed are oligonucleotides for inhibiting or reducing expression of MC2R or CYP11B1, and lipid conjugated oligonucleotides for targeting MC2R or CYP11B1 in the adrenal gland. Also disclosed are methods for treating, preventing, and alleviating diseases associated with MC2R and/or CYP11B1 expression, such as Cushing's Disease, Cushing's Syndrome, Familial Glucocorticoid Deficiency, hereditary adrenocortical unresponsiveness to ACTH, Congenital Adrenal Hypoplasia, familial Addison's Disease, or other cortisol synthesis or signaling pathway associated conditions or complications, comprising administering an effective amount of the oligonucleotides, alone or in combination to a patient. L'invention divulgue des oligonucléotides pour inhiber ou réduire l'expression de MC2R ou CYP11B1, et des oligonucléotides conjugués à des lipides pour cibler MC2R ou CYP11B1 dans la glande surrénale. L'invention divulgue également des méthodes de traitement, de prévention et d'atténuation de maladies associées à l'expression de MC2R et/ou CYP11B1, telles que la maladie de Cushing, le syndrome de Cushing, le déficit familial isolé en glucocorticoïdes, la résistance à l'Adrénocorticotrophine Hormone (ACTH) héréditaire, l'hyperplasie congénitale des surrénales, la maladie d'Addison familiale, ou d'autres affections ou complications associées à la synthèse de cortisol ou à la voie de signalisation, comprenant l'administration d'une quantité efficace des oligonucléotides, seuls ou en combinaison à un patient.</description><language>eng ; fre</language><subject>CHEMISTRY ; DERIVATIVES THEREOF ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SUGARS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230413&amp;DB=EPODOC&amp;CC=WO&amp;NR=2023060141A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230413&amp;DB=EPODOC&amp;CC=WO&amp;NR=2023060141A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JOSHI, Sanjana</creatorcontrib><creatorcontrib>DUDEK, Henrik</creatorcontrib><creatorcontrib>DISTEFANO, Peter Victor</creatorcontrib><creatorcontrib>ABRAMS, Marc</creatorcontrib><creatorcontrib>WONDIMU, Elisabeth</creatorcontrib><title>COMPOSITIONS AND METHODS FOR INHIBITING MELANOCORTIN 2 RECEPTOR AND CYTOCHROME P450 11B1 EXPRESSION</title><description>Disclosed are oligonucleotides for inhibiting or reducing expression of MC2R or CYP11B1, and lipid conjugated oligonucleotides for targeting MC2R or CYP11B1 in the adrenal gland. Also disclosed are methods for treating, preventing, and alleviating diseases associated with MC2R and/or CYP11B1 expression, such as Cushing's Disease, Cushing's Syndrome, Familial Glucocorticoid Deficiency, hereditary adrenocortical unresponsiveness to ACTH, Congenital Adrenal Hypoplasia, familial Addison's Disease, or other cortisol synthesis or signaling pathway associated conditions or complications, comprising administering an effective amount of the oligonucleotides, alone or in combination to a patient. L'invention divulgue des oligonucléotides pour inhiber ou réduire l'expression de MC2R ou CYP11B1, et des oligonucléotides conjugués à des lipides pour cibler MC2R ou CYP11B1 dans la glande surrénale. L'invention divulgue également des méthodes de traitement, de prévention et d'atténuation de maladies associées à l'expression de MC2R et/ou CYP11B1, telles que la maladie de Cushing, le syndrome de Cushing, le déficit familial isolé en glucocorticoïdes, la résistance à l'Adrénocorticotrophine Hormone (ACTH) héréditaire, l'hyperplasie congénitale des surrénales, la maladie d'Addison familiale, ou d'autres affections ou complications associées à la synthèse de cortisol ou à la voie de signalisation, comprenant l'administration d'une quantité efficace des oligonucléotides, seuls ou en combinaison à un patient.</description><subject>CHEMISTRY</subject><subject>DERIVATIVES THEREOF</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SUGARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjEEKwjAURLtxIeodPrgWkrR236a_JmDyQxJQV6WUuBIt1PtjBA_gapiZN7MuJknGUdBRkw3Q2A4MRkVdgJ48aKt0mzt7yvG5sSTJZwcCPEp0MSPfibxFksqTQXDVkQHnLQe8Oo8h5N9tsbqPjyXtfrop9j1GqQ5pfg1pmccpPdN7uJBgomQ14xVvRPkf9QHNojS7</recordid><startdate>20230413</startdate><enddate>20230413</enddate><creator>JOSHI, Sanjana</creator><creator>DUDEK, Henrik</creator><creator>DISTEFANO, Peter Victor</creator><creator>ABRAMS, Marc</creator><creator>WONDIMU, Elisabeth</creator><scope>EVB</scope></search><sort><creationdate>20230413</creationdate><title>COMPOSITIONS AND METHODS FOR INHIBITING MELANOCORTIN 2 RECEPTOR AND CYTOCHROME P450 11B1 EXPRESSION</title><author>JOSHI, Sanjana ; DUDEK, Henrik ; DISTEFANO, Peter Victor ; ABRAMS, Marc ; WONDIMU, Elisabeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023060141A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>DERIVATIVES THEREOF</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SUGARS</topic><toplevel>online_resources</toplevel><creatorcontrib>JOSHI, Sanjana</creatorcontrib><creatorcontrib>DUDEK, Henrik</creatorcontrib><creatorcontrib>DISTEFANO, Peter Victor</creatorcontrib><creatorcontrib>ABRAMS, Marc</creatorcontrib><creatorcontrib>WONDIMU, Elisabeth</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JOSHI, Sanjana</au><au>DUDEK, Henrik</au><au>DISTEFANO, Peter Victor</au><au>ABRAMS, Marc</au><au>WONDIMU, Elisabeth</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPOSITIONS AND METHODS FOR INHIBITING MELANOCORTIN 2 RECEPTOR AND CYTOCHROME P450 11B1 EXPRESSION</title><date>2023-04-13</date><risdate>2023</risdate><abstract>Disclosed are oligonucleotides for inhibiting or reducing expression of MC2R or CYP11B1, and lipid conjugated oligonucleotides for targeting MC2R or CYP11B1 in the adrenal gland. Also disclosed are methods for treating, preventing, and alleviating diseases associated with MC2R and/or CYP11B1 expression, such as Cushing's Disease, Cushing's Syndrome, Familial Glucocorticoid Deficiency, hereditary adrenocortical unresponsiveness to ACTH, Congenital Adrenal Hypoplasia, familial Addison's Disease, or other cortisol synthesis or signaling pathway associated conditions or complications, comprising administering an effective amount of the oligonucleotides, alone or in combination to a patient. L'invention divulgue des oligonucléotides pour inhiber ou réduire l'expression de MC2R ou CYP11B1, et des oligonucléotides conjugués à des lipides pour cibler MC2R ou CYP11B1 dans la glande surrénale. L'invention divulgue également des méthodes de traitement, de prévention et d'atténuation de maladies associées à l'expression de MC2R et/ou CYP11B1, telles que la maladie de Cushing, le syndrome de Cushing, le déficit familial isolé en glucocorticoïdes, la résistance à l'Adrénocorticotrophine Hormone (ACTH) héréditaire, l'hyperplasie congénitale des surrénales, la maladie d'Addison familiale, ou d'autres affections ou complications associées à la synthèse de cortisol ou à la voie de signalisation, comprenant l'administration d'une quantité efficace des oligonucléotides, seuls ou en combinaison à un patient.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2023060141A2
source esp@cenet
subjects CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SUGARS
title COMPOSITIONS AND METHODS FOR INHIBITING MELANOCORTIN 2 RECEPTOR AND CYTOCHROME P450 11B1 EXPRESSION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A44%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JOSHI,%20Sanjana&rft.date=2023-04-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023060141A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true